Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy.

J Elkahwaji1, M A Robin, A Berson

  • 1INSERM U481 and Centre de Recherche sur les Hépatites Virales (Association Claude Bernard), Hôpital Beaujon, Clichy, France.

Biochemical Pharmacology
|March 23, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

ESMO open·2024
Same author

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.

ESMO open·2024
Same author

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.

ESMO open·2024
Same author

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.

ESMO open·2021
Same journal

Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease.

Biochemical pharmacology·2026
Same journal

The organelle-targeting duality of nanomaterials: physicochemical property-guided therapeutic effects and toxicological outcomes.

Biochemical pharmacology·2026
Same journal

The central role of endoplasmic reticulum stress in Parkinson's disease and targeted therapeutic strategies.

Biochemical pharmacology·2026
Same journal

Mechanisms involved in the regulation of carbohydrate and lipid metabolism by oleanane-type pentacyclic triterpenes.

Biochemical pharmacology·2026
Same journal

Myricitrin alleviates paraquat-induced acute lung injury via PERK pathway to attenuate endoplasmic reticulum stress and mitochondrial dysfunction.

Biochemical pharmacology·2026
Same journal

Design, synthesis, and biological evaluation of Combretastatin A4 dimers for the treatment of hepatocellular carcinoma.

Biochemical pharmacology·2026
See all related articles

High doses of Interleukin-2 (IL-2) may reduce cytochrome P450 (CYP) enzyme activity in cancer patients. This study investigated IL-2

Area of Science:

  • Pharmacology
  • Hepatology
  • Oncology

Background:

  • Interleukin-2 (IL-2) is known to decrease cytochrome P450 (CYP) expression in rats.
  • The impact of high-dose IL-2 on human CYP enzymes, crucial for drug metabolism, remains largely undetermined.

Purpose of the Study:

  • To evaluate the effect of varying doses of human recombinant IL-2 on hepatic CYP enzyme levels and activity in cancer patients undergoing surgery.

Main Methods:

  • Patients with liver metastases received daily doses of IL-2 (0-12x10^6 units/m2) before hepatectomy.
  • Liver tissue samples were analyzed for CYP1A2, CYP2C, CYP2E1, and CYP3A4 expression and associated enzyme activities.

Main Results:

  • Low-to-moderate IL-2 doses (3-6x10^6 units/m2) did not significantly alter CYP levels or activity.

Related Experiment Videos

  • High IL-2 doses (9-12x10^6 units/m2) significantly reduced mean CYP1A2, CYP2C, CYP2E1, and CYP3A4 by 37-60%.
  • Total CYP and key monooxygenase activities (methoxyresorufin O-demethylation, erythromycin N-demethylation) were significantly decreased by high-dose IL-2.

    • Conclusions:

    • High-dose Interleukin-2 administration in cancer patients can lead to a significant decrease in hepatic cytochrome P450 enzymes and their metabolic activities.
    • These findings highlight potential drug-drug interaction risks and altered drug metabolism in patients receiving high-dose IL-2 therapy.